--- title: 'Clinical Scientist (CONSULTANT) at Entrada Therapeutics' canonical: 'https://feeny.ai/job/clinical-scientist-consultant-entrada-therapeutics-boston-sn71hza1h4vt' type: 'job' last_seen: '2026-10-18' --- # Clinical Scientist (CONSULTANT) at Entrada Therapeutics - **Company:** Entrada Therapeutics - **Location:** Boston, MA - **Posted:** 2026-10-15 - **Last confirmed live:** 2026-10-18 - **Apply:** https://job-boards.greenhouse.io/entradatherapeutics/jobs/5266416007 ## Job description The Organization What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1). 2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670). We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families. The Perfect Addition to Our Team You are excited about the opportunity to spearhead data review and partner on innovative processes to set the company up for success through subsequent phases of clinical development. You have a strategic mindset but have no problem rolling up your sleeves to implement the work that needs to get done. You are a self-starter and an effective communicator. You take accountability for known project responsibilities, but you can also easily adapt and accommodate the unexpected. You thrive in a fast paced, highly collaborative, flexible working environment. The Opportunity This individual will be highly motivated and experienced clinical researcher interested in working on all phases of clinical development. Reporting to the Executive Director, Clinical Development, this individual will provide both a strategic lens and hands on support in designing, developing and implementing strategies to support clinical trials in Duchenne muscular dystrophy, utilizing Entrada’s unique EEV technology. The right candidate will bring scientific rigor, deep expertise in clinical data review, and a passion for improving quality of life for patients and families impacted by rare neuromuscular disorders. ## Responsibilities - Support interpretation of clinical data to generate high quality summaries and insights to support regulatory filings, publications and scientific communications. - Collaborate cross-functionally with Medical Directors, Clinical Operations, Data Management, Biostatistics, and Business Operations to help drive execution across clinical phases. - In partnership with Medical Directors, lead or support the authoring of selected sections of clinical study reports. - Support real-time data review, identify trends in safety and efficacy data and assessing protocol compliance including protocol deviation reviews, escalating to Medical Monitor(s) where appropriate. - Identify scientific and/or clinical quality issues to discuss with PI and study sites, partnering with study team and GCP quality team members for escalations as needed. - Consultant on the design of study-specific case report form (CRF) and author study-specific sections of the CRF completion guidelines, ensuring CRFs are aligned with study requirements during user acceptance testing. - Perform safety and efficacy reviews in preparation for DMC, in conjunction with Medical Director and other internal stakeholders, analyzing trends within and across programs. - Collaborate with Business Operations and Data Management to lead development and innovation of department clinical data technology access, retention, and visualization strategy, to support trend identification across programs. - Support innovation and strategy for the integration of new tools and technologies into phase 1-3 clinical studies. The Necessities At Entrada, our passion for science, our devotion to patients and our values drives our behavior: - Humanity - We genuinely care about patients and about one another. - Tenacity - We are relentless and persistent in the pursuit of developing therapies for patients. - Creativity - We are creative problem solvers. - Collaboration - We are more than the sum of our parts. - Curiosity - We have a growth mindset and push conventional thought and theory. To thrive on our team, you will need to come with: - Ph.D., PharmD, MD, Nursing, or Clinical Master’s degree in a scientifically relevant field, with 6 + years of clinical development experience within the biotechnology or pharmaceutical industry. - Proven understanding of clinical development processes to serve as subject matter expert for phase 1-3 clinical studies. - Previous experience identifying trends and setting risk mitigation strategies in partnership with Medical teams within clinical studies. - Demonstrated experience in the design and execution of clinical trials and a strong understanding of GCP/ICH guidelines and regulatory expectations. - Experience in rare disease and/or neuromuscular disease is strongly preferred. - Skilled in Microsoft suite as well as innovative data review tools (ie. patient profiles, report generating tools) - Self-motivated, demonstrated success in delivering assigned tasks according to timelines. - Demonstrated history of creative problem-solving and learning ability. - Ability to interpret complex data and communicate clearly with both scientific and non-scientific stakeholders. - Strong data analysis, data visualization and communication skills, with ability to write clear, accurate and concise documents, construct informative figures, and present to diverse audiences. - Desire to work in an innovative and collaborative, fast paced, mission driven environment, taking on new challenges with an adaptable mindset. - This is a US based remote, contract position with 40 hours per week expected, with preference given to local New England based candidates. This role will require a minimum quarterly travel to the Entrada Therapeutics Headquarters located in Boston, MA. #LI-Remote #LI-JF1 ## Equal Opportunity Employer Entrada Therapeutics is an equal opportunity employer. Qualified candidates will receive consideration for employment without regard to race, color, religion, national origin, gender, sexual orientation, gender identity or expression, age, mental or physical disability, and genetic information, marital status, citizenship status, military status, protected veteran status or any other category protected by law. Third Party Staffing Agencies Entrada does not accept unsolicited resumes from any source other than directly from candidates. For the protection of all parties involved in the recruiting process, resumes will only be accepted from recruiters/agencies if a signed agreement is in place at the inception of the recruiting effort and authorized for a specified position. Unsolicited resumes sent to Entrada from recruiters/agencies do not constitute any type of relationship between the recruiter/agency and Entrada and do not obligate Entrada to pay fees if we hire from those resumes. Privacy Statement Entrada Therapeutics, Inc. (the “Entrada,” “we,” “us,” or “our”) respects your privacy and we want you to be familiar with how we collect, use, share, or otherwise process, your Personal Information. Please reference our privacy statement [here](https://www.entradatx.com/privacy-notice)to understand how and when your data is being used. ## About Entrada Therapeutics ## Company Overview - **One-liner**: Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary Endosomal Escape Vehicle (EEV™) platform to deliver genetic medicines to previously inaccessible intracellular targets for devastating diseases. - **Entity Type**: Public (NASDAQ: TRDA) - **Headquarters**: Boston, Massachusetts, United States - **Founded**: 2016 - **Founders**: Not publicly listed on the company website; leadership team includes CEO Dipal Doshi, CFO Kory Wentworth, and President of R&D Natarajan Sethuraman. ## Core Business - **Primary industry**: Biotechnology – genetic medicines and intracellular therapeutics - **Target customers**: B2B (partnerships with pharma like Vertex) and ultimately patients with rare neuromuscular and retinal diseases - **Mission**: To treat devastating diseases with intracellular therapeutics, focusing on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and inherited retinal diseases. ## Products & Services - **EEV™ Platform**: A proprietary, modular delivery technology designed to enable efficient intracellular delivery of oligonucleotides, proteins, and other therapeutics into a wide range of tissues (muscle, retina, etc.) with an improved therapeutic index. - **Clinical-stage programs (DMD franchise)**: - ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51 – exon-skipping oligonucleotides for DMD patients amenable to skipping exons 44, 45, 50, and 51. Multiple programs have advanced into clinical trials in the U.K., EU, and U.S. - **Collaboration program**: - VX-670 (with Vertex Pharmaceuticals) – a clinical-stage therapy for myotonic dystrophy type 1 (DM1). - **Pipeline (preclinical)**: Additional programs in neuromuscular and inherited retinal diseases. ## Market Standing - **Valuation/Market Cap**: $711.3 million (as of mid-2026, per LinkedIn data) - **Key Metric (Revenue)**: $25.4 million annual revenue (2025/2026 estimate from LinkedIn) - **Notable Investors/Partners**: Vertex Pharmaceuticals (strategic collaboration); publicly traded with institutional investors - **Growth Signals**: - IPO in 2021 - 2026 described as a “catalyst-rich period” with multiple clinical data readouts expected - Four clinical-stage DMD programs by year-end 2026 - Positive safety data from ELEVATE-45-201 study leading to dose escalation (10 mg/kg cohort) - Headcount of 168 employees (down ~6% YoY, indicating possible restructuring or natural attrition) ## Competitive Advantages - **Proprietary EEV™ Platform**: Enables intracellular delivery of large molecules that cannot cross cell membranes, unlocking “undruggable” targets – a significant differentiator in the genetic medicine space. - **Modular and versatile**: Platform can be applied across multiple therapeutic areas (neuromuscular, retinal, metabolic) and modalities (oligonucleotides, proteins, gene editors). - **Deep DMD franchise**: Entrada is building one of the broadest exon-skipping pipelines for DMD, targeting multiple patient subpopulations. - **Strategic partnership with Vertex**: Validates the platform and provides co-development resources for DM1. ## Strategic Focus - **Near-term**: Deliver clinical proof-of-concept for DMD programs (data readouts through 2026) and advance VX-670 in DM1. - **Pipeline expansion**: Continue to broaden the EEV platform into new tissues and disease areas, including inherited retinal diseases and metabolic disorders. - **Commercial readiness**: Build internal capabilities for potential future product launches while maintaining a lean, high-impact R&D organization. ## Why Work Here - **Culture**: Described as a “tight-knit team of experts and leaders” with a mission-driven, collaborative, and high-energy environment. Values include humanity, curiosity, and a growth mindset. - **Diversity & Inclusion**: As of October 2025, 58% of employees identify as women, 45% as Asian, Hispanic, Latino, African American, or two or more races; 64% of senior leadership and board are women and minorities. Employee Resource Groups (ERGs) are active. - **Work Model**: Flexible working – role-dependent remote options; employees choose where they work best. Commuter benefits (up to $325/month) for those who come to the Boston Seaport office. - **Benefits**: Comprehensive – fully subsidized lunches/snacks, $500 wellbeing stipend, gender-inclusive parental leave, education reimbursement, mental health and financial coaching, HSA contributions, and milestone celebrations. - **Perks**: In-office fuel (free food/drinks), regular team events, and a strong emphasis on work-life balance. - **Open Roles**: Positions include clinical trial management, regulatory affairs, drug substance development, IT support, and more – posted on Greenhouse. ## Sources 1. [entradatx.com](https://www.entradatx.com/) – Company overview, platform, pipeline, mission 2. [entradatx.com/about](https://www.entradatx.com/about) – Leadership team, company history 3. [entradatx.com/careers](https://www.entradatx.com/careers) – Culture, benefits, diversity stats, open positions 4. [linkedin.com/company/entradatx](https://www.linkedin.com/company/entradatx) – Headcount, revenue, market cap, industry classification 5. [job-boards.greenhouse.io/entradatherapeutics](http://job-boards.greenhouse.io/entradatherapeutics) – Current job listings ## Other roles at Entrada Therapeutics - [Manager, Commercial Strategy Analytics](https://feeny.ai/job/manager-commercial-strategy-analytics-entrada-therapeutics-boston-93h032mf0742) — Boston, MA - [SEC Reporting & Technical Accounting Consultant](https://feeny.ai/job/sec-reporting-technical-accounting-consultant-entrada-therapeutics-boston-tbhf4v28p0a8) — Boston, MA - [Senior Clinical Operations Contractor](https://feeny.ai/job/senior-clinical-operations-contractor-entrada-therapeutics-boston-ywx802nhvaen) — Boston, MA - [Associate Director, Drug Product Development & Manufacturing](https://feeny.ai/job/associate-director-drug-product-development-manufacturing-entrada-therapeutics-p593cry5gk61) — Boston, MA - [Associate Director, Analytical Development & Quality Control](https://feeny.ai/job/associate-director-analytical-development-quality-control-entrada-therapeutics-z1f7fbqpchmp) — Boston, MA - [Director, Regulatory Writing](https://feeny.ai/job/director-regulatory-writing-entrada-therapeutics-boston-ab86t5fmrhhn) — Boston, MA